SARC Career Development Program

CTOS meeting London England

November 14, 2008

Laurence BakerJennifer Keene

SARC’s Goals

• Engage expert sarcoma researchers and clinicians to improve outcome of patients with sarcoma

• Collaboration of pediatric,medical, surgical, orthopaedic and radiation oncologists, pathologists, radiologists, medical geneticists, and molecular biologists

• Progress against sarcomas depends on sustained, collegiate effort among these experts

Background

• Grant from Roche to SARC– Awarded October 2007– $2.5 million unrestricted grant – To promote sarcoma career development

• How does SARC go about designing their own Career Development Award??

– Recipient / Eligibility characteristics– Terms of Award– Award Process

SARC Career Development Award Committee

• Laurence Baker*• Jean Yves Blay*• John Crowley• Marie Debiec-Rychter• Jonathan Fletcher• Richard Gorlick

• Lee Helman*• Steve Ritland• Mark Thornton• Matt Van de Rijn• Jaap Verweij• Jay Wunder

* Co-Chair

Interviews: Young Investigator Awardees

• More freedom

• Protected time challenging

• Changes in mentor

• Pay off loans

Awards for Comparison

• American Society of Hematology (ASH)• Leukemia & Lymphoma (L & L) • American Cancer Society (ACS)• American Society of Clinical Oncology (ASCO)• National Institute of Health (NIH)

– K08– K12– K22– K23

ASCO – CDA Criteria

• Physician– 1+ years post final

subspecialty training

• Full-time faculty appointment

• Completed postdoctoral/post-fellowship research

• Demonstrated ability for independent investigator-initiated clinical research

• Active member of ASCO

• Expect to spend 50% of time dedicated to Research

• Must have a mentor from their institution and institutional letter of support

• Applicants with existing career development awards (K23, K08, etc.) will not be considered for funding

ASCO – ACRA in Sarcoma

• Physician is 5-10 years post final subspecialty training

• Full-time faculty appointment

• Demonstrated ability for independent investigator-initiated clinical research

• Active member of ASCO

• Expect to spend 75% effort dedicated to research

• $450,000 over 3 years

• Raphael Rousseau MD, PhD– Nanoparticle-based targeting

Tumor neoangiogenesis to improve surgical resection in Osteosarcoma

• Scott Schuetze, MD PhD– Study of sirolimus combined

with cyclophosphamide in sarcoma

NCI K08• Mentored Clinical Scientist Development Award

the gold standard• Annually for 5 years

• 75K per year plus fringe benefits

• 30K research development expenses

• 75% full-time professional effort to research career development

NIH K08 Awards for Sarcoma Research

• 2007, “Tumor Suppressors in Ewing’s Sarcoma”, Stephen L. Lessnick (University of Utah)

• 2007, “Tumor Antigen Presentation in Mice Developing Cancer”, Kevin F. Staveley-O’Carroll (Penn State Univ, Hershey Med Ctr)

• 2007, “An Animal Model for Kaposi’s Sarcoma”, Christopher H. Parsons (Med Univ of SC)

• 2007, “RAS-Mediated ERBB Signaling in Osteosarcoma”, Dennis P. Hughes (MDACC)

• 2007, “Secreted WNT Inhibitors in the Biology of Osteosarcoma”, Bang H. Hoang (U of C Irvine)

NCI K12

• Paul Calabresi Award is a multi- and transdisciplinary institutional training award supporting the research career development of clinicians in clinical Oncology

• Awards (renewable) for up to $750,000 annually in direct costs or $1,050,000 annually (programs combining clinicians and PhDs) to institutions for up to five years

Funded K12 Grants

• Mark R. Albertini, University of Wisconsin

• Robert C. Bast, Univ of TX, MDACC

• Irwin D. Bernstein, Fred Hutchinson CRC

• Bruce A. Chabner, Massachusetts General

• Ross C. Donehower, Johns Hopkins

• James S. Economou, U of CA Los Angeles

• Stephen G. Emerson, Penn• Stanton L. Gerson, Case

Western Reserve University

• Kenneth R. Hande, Vanderbilt University

• Lynn C. Hartmann, Mayo Clinic Rochester

• Herbert Kim Lyerly, Duke University

• Robert L. Martuza, Massachusetts General

• David G. Poplack, Baylor College of Medicine

• Gary K. Schwartz, MSKCC• Kenneth S. Zuckerman,

University of S. Florida

NCI K23

• Mentored Patient-Oriented Research Career Development Award

• Support for up to 5 years of combined didactic and mentored research

• Not renewable

• 75% effort to research and research career development

• 75K per year for salary and fringe benefits

• 30K for research development support

• 8% facilities and administrative costs (formerly called indirect costs)

NIH K23 Awards for Sarcoma Research

• 2007,“Mechanism/Activity/Resistance/ Gleevec and GIST”– Jonathan Trent (MD Anderson)

• 2007, “HSP as a Target for the Treatment of Childhood Cancer”– Rochelle Bagatell (University of Arizona)

SARC Career Development Award• Initial awards begin July

2009

• Award $100,000/yr for 3 years

• Candidate within 5 years of completion of final training and must be physician

• Candidates must be from Europe, Canada or United States

• Candidate may not be supported by another career development award

• Maximum flexibility in funding– Time commitment is

important criteria

• If candidate awarded a research grant during term of CDA– SARC CDA will continue

with new research plan

Institutional Commitment

• Parent institutional commitment important• Required letter from mentor with detail of

mentoring plan• Required letter from chairperson or

equivalent detailing– role of individual on faculty– details regarding protected time– department/institutional resources provided

• space, core support, other

SARC Grant Process• Submit 2 page letter and CV

• Applications review/invite full application– Complete application using

electronic format www.sarctrials.org

• Timelines– Jan 1, 2009

• Letter of interest– Feb 1, 2009

• Invited full proposal– March 15, 2009

• Proposal due– May 1, 2009

• Notice of funding– July 1, 2009

• Funding begins

Jennifer Keene and Julia Baker Keene